Skip to content

Effectiveness and safety of Minichek in male patients with hairfall.

An open-label, single arm non-comparative study to assess effectiveness and safety of Minichek (Minoxidil 5% ) in the management of Androgenic Alopecia.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/10/016214
Enrollment
50
Registered
2018-10-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L649- Androgenic alopecia, unspecified Health Condition 2: L649- Androgenic alopecia, unspecified

Interventions

Intervention1: Minichek: Dosage and Administration Minoxidil 5%(Minichek 5%) is indicated for the treatment of androgenic alopecia Minichek topical solution is used for external use only. It should be

Sponsors

Dr Narendra G Patwardhan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male patients who are >=18 to 2. Patient suffering from Androgenic alopecia. 3. Patient willing to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patient suffering from non-androgenic alopecia. 2. Evidence of dermatological disease as revealed by history, physical examination or laboratory assessment which may interfere with administration or assessment of study medication. 3. Current use of dermatological drugs/preparations which may interfere with study evaluation (Finasteride or any other hormonal treatment). 4. Intolerance to any of the ingredients of the formulation. 5. Current alcohol or drug abuse. 6. Patients viewed by the investigator as not being able to complete the study. 7. Any procedures for hair enhancement and curling or straightening techniques. 8. Patients having participated in a clinical trial in last 30 days. 9. Patients with a history of a migraine.

Design outcomes

Primary

MeasureTime frame
Effects of Minichek 5% treatment on change in Anagen/Telogen ratio with androgenetic alopecia.Timepoint: From baseline to day 45, day 90, day 135 and day 180.

Secondary

MeasureTime frame
Effects of Minichek 5% treatment on change in Hair diameter.Timepoint: From Baseline to day 45, day 90, day 135 and day 180.;Investigator and Patientâ??s global assessment for effectiveness.Timepoint: At day 90 and day 180 on the basis of global photographs. ;Investigator and Patientâ??s global assessment for tolerability.Timepoint: At day 45, day 90, day 135 and day 180.;Safety assessment of the Minichek 5% in the treatment of AGA.Timepoint: At day 45, day 90, day 135 and day 180.;Trichoscopy Evaluations of the Minichek 5% treatment at day 45, day 90, day 135 and day 180.Timepoint: At day 45, day 90, day 135 and day 180.

Countries

India

Contacts

Public ContactDr Narendra G Patwardhan

Kelkar Nursing Home

ngpatwardhan@gmail.com09822057712

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026